Biotech News

BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth

BioCryst Pharmaceuticals (BCRX)BioCryst PharmaceuticalsCompany update

—Supports BioCryst’s evolution toward a more disciplined R&D model centered on external innovation— RESEARCH TRIANGLE PARK, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the formation of a Scientific Advisory Board (SAB) comprising seven

Related news

BCRXBioCryst Pharmaceuticals2026-10-29 11:00 EST

BioCryst to Present New Data for ORLADEYO® (berotralstat) and Navenibart at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting

BCRXBioCryst Pharmaceuticals2026-11-13 12:00 EST

BioCryst Presents New Real-World Evidence Showing Reduced Angioedema-Related Medical Visits After Switching to ORLADEYO® (berotralstat) at ACAAI 2026 Annual Scientific Meeting

RHHBYRoche Holdings AG2026-09-17 18:30 EST

Roche announces grand opening of its Innovation Center Boston to drive advancements in Cardiovascular, Renal and Metabolic diseases

RHHBYRoche Holdings AG2026-11-10 06:00 EST

Roche presents new data across pharmaceuticals and diagnostics from its growing Alzheimer’s disease portfolio at CTAD 2026

MNPRMonopar2026-11-09 13:00 EST

Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD – The Liver Meeting® 2026

ARWRArrowhead Pharmaceuticals2026-11-02 12:30 EST

Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026

RCKTRocket Pharmaceuticals2026-10-07 13:36 EST

Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar

ARWRArrowhead Pharmaceuticals2026-09-29 11:30 EST

Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

PHVSPharvaris2026-10-29 10:50 EST

Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting

ENTAEnanta Pharmaceuticals2026-10-26 11:00 EST

Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)

BioCryst Pharmaceuticals

Rare-Disease Drug Development BioCryst Pharmaceuticals discovers, develops and commercializes small-molecule medicines for rare diseases. Its portfolio combines a marketed hereditary angioedema franchise with clinical programs targeting additional protein-mediated disorders. ORLADEYO Commercial Franchise ORLADEYO is an oral preventive...

Recent company news

Stock data

Close
7.32 USD
Market cap
2.12B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States